New Cancer Gene Therapy Data Have Been Reported by Researchers at Medical University-Sofia

Strategic Insights -

Researchers from Medical University-Sofia have published new findings on cancer gene therapy, with a focus on overcoming resistance and toxicity in anticancer therapy. The study, published in the journal Molecules, aimed to compare the therapeutic combinations of various platinum-based anticancer agents, including Cisplatin, Carboplatin, Oxaliplatin, and others. The researchers explored strategies for improving the antitumor effect against different cancers, including combination therapy with various anticancer agents, modulators of resistant mechanisms, signaling protein inhibitors, and immunotherapeutic drugs.

Key Takeaways:

  • The study highlights the challenges of anticancer therapy, including resistance and toxicity, and explores strategies for overcoming these limitations.
  • A total of 3000 Cisplatin derivatives were tested as antitumor agents, with most being rejected due to toxicity.
  • The research identified various strategies for improving the antitumor effect, including combination therapy, Pt IV prodrugs, targeted nanocarriers, and synergistic combinations of anticancer agents.
  • The study lists a total of 26 anticancer agents used in combination therapy, including Fluorouracil, Gemcitabine, Cytarabine, and others.
  • The researchers found that combination therapy with various anticancer agents, modulators of resistant mechanisms, signaling protein inhibitors, and immunotherapeutic drugs can enhance the therapeutic efficacy against different cancers.

Statistics:

  • 3000 Cisplatin derivatives were tested as antitumor agents, with most being rejected due to toxicity.
  • The study identified 26 anticancer agents used in combination therapy.
  • The researchers explored 4 strategies for improving the antitumor effect: combination therapy, Pt IV prodrugs, targeted nanocarriers, and synergistic combinations of anticancer agents.

Sources:

  • NewsRx press release (May 10, 2022).
  • "Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases." Molecules, vol. 27, no. 12, 2022, p. 2466.